过表达TSR2通过下调PI3K/AKT信号通路抑制胃癌细胞的增殖和侵袭

doi:10.12122/j.issn.1673-4254.2024.05.13

摘要/Abstract

摘要：

目的探讨TSR2核糖体成熟因子在胃癌中的表达情况及其与胃癌恶性演进的相关性，并分析其潜在的作用机制。方法纳入105例胃癌患者资料，分析TSR2在胃癌组织中表达水平及其对胃癌恶性进展、术后5年生存率的影响；GO及KEGG富集分析预测TSR2的生物学功能及可能的作用机制；通过慢病毒转染技术上调和下调TSR2在胃癌细胞系（MGC-803）的表达水平，并采用CCK-8、Transwell评估其对MGC-803细胞增殖、侵袭及迁移的影响；Western blot检测p-PI3K、p-AKT表达。结果 TSR2在胃癌组织的表达水平显著低于癌旁组织（P<0.001），且TSR2的表达水平与CEA、CA19-9、T分期及N分期相关（P<0.05）。单因素联合多因素分析显示，TSR2低表达（P=0.020）、CEA≥5 μg/L（P=0.021）、CA19-9≥37 kU/L（P=0.001）、T₃~T₄分期（P=0.039）和N₂~N₃分期（P=0.027）是独立影响胃癌患者施行根治术后5年生存率的风险因子。生存分析结果显示，TSR2表达水平与胃癌患者术后5年生存率呈正相关（P<0.001）。生物信息学富集分析预测TSR2的功能可能与PI3K/AKT信号通路相关。CCK-8和Transwell实验结果显示，上调TSR2可抑制胃癌细胞的增殖、迁移和侵袭（P<0.05），下调则反之（P<0.05）。Western blot结果显示过表达TSR2可下调胃癌细胞中磷脂肌醇3激酶（PI3K）和蛋白激酶B（AKT）的磷酸化，敲低则反之（P<0.05）。结论 TSR2在胃癌组织中低表达并影响患者预后，其可能与下调PI3K/AKT信号通路抑制胃癌细胞的增殖、侵袭与迁移有关。

关键词: 胃癌, TSR2核糖体成熟因子, PI3K/AKT, 增殖, 侵袭

Abstract:

Objective To investigate the expression of TSR2 in gastric cancer and explore its correlation with progression of gastric cancer and the possible mechanism. Methods We retrospectively analyzed TSR2 expression in clinical specimens from 105 gastric cancer patients and the impact of TSR2 expression level on disease progression and 5-year postoperative survival of the patients. GO and KEGG enrichment analyses were used to predict the biological functions and mechanisms of TSR2. In gastric cancer MGC-803 cells with lentivirus-mediated TSR2 overexpression or knockdown, the changes in cell proliferation, invasion, and migration were assessed with CCK-8 and Transwell assays, and the expressions of p-PI3K and p-AKT were detected using Western blotting. Results TSR2 expression was significantly lower in gastric cancer tissues than in the adjacent tissues with significant correlations with CEA level, CA19-9 level, and T and N staging (P<0.05). A low TSR2 expression, CEA≥5 μg/L, CA19-9≥37 kU/L, T₃-T₄ stages, and N₂-N₃ staged were identified as independent risk factors affecting 5-year survival rate of the patients following radical surgery (P<0.05), and a high TSR2 expression was associated with a higher 5-year survival rate of the patients (P<0.001). Bioinformatics analysis suggested the functional involvement of TSR2 with the PI3K/AKT signaling pathway. MGC-803 cells overexpressing TSR2 showed significantly lowered proliferation, migration, and invasion capacities (P<0.05), while TSR2 knockdown produced the opposite effects (P<0.05). Western blotting showed that TSR2 overexpression reduced the phosphorylation of PI3K and AKT, and TSR2 knockdown caused the opposite changes in MGC-803 cells (P<0.05). Conclusion TSR2 is lowly expressed in gastric cancer tissues to adversely affect the patients' prognosis, and its overexpression inhibits gastric cancer cell proliferation, invasion, and migration possibly by downregulating the PI3K/AKT pathway.

Key words: gastric cancer, TSR2 ribosome maturation factor, PI3K/AKT, proliferation, invasion

夏勇生, 王炼, 陈孝华, 张雨路, 孙奥飞, 陈德利. 过表达TSR2通过下调PI3K/AKT信号通路抑制胃癌细胞的增殖和侵袭[J]. 南方医科大学学报, 2024, 44(5): 913-919.

Yongsheng XIA, Lian WANG, Xiaohua CHEN, Yulu ZHANG, Aofei SUN, Deli CHEN. TSR2 overexpression inhibits proliferation and invasion of gastric cancer cells by downregulating the PI3K/AKT signaling pathway[J]. Journal of Southern Medical University, 2024, 44(5): 913-919.

图/表 8

图1 TSR2在胃癌及癌旁组织中的表达情况

Fig.1 Expression of TSR2 in gastric cancer and adjacent tissues. A: TSR2 is lowly expressed in gastric cancer tissue. B: TSR2 is highly expressed in adjacent tissue. C: Relative IOD value of TSR2 (n=105). *P<0.05 vs adjacent tissues.

表1 胃癌组织中TSR2的表达量与恶性进展参数的关系

Tab.1 Correlation between TSR2 expression and progression of gastric cancer [n (%)]

Factors	n	TSR2 expression		χ ²	P
Factors	n	Low (n=53)	High (n=52)	χ ²	P
Gender				0.023	0.880
Male	74	37 (50.0%)	37 (50.0%)
Female	31	16 (51.6%)	15 (48.4%)
Age (year)				0.015	0.903
<60	41	21 (51.2%)	20 (48.8%)
≥60	64	32 (50.0%)	32 (50.0%)
CEA (μg/L)				6.940	0.008
<5	49	18 (36.7%)	31 (63.3%)
≥5	56	35 (62.5%)	21 (37.5%)
CA19-9 (kU/L)				17.720	<0.001
<37	47	13 (27.7%)	34 (72.3%)
≥37	58	40 (69.0%)	18 (31.0%)
Tumor size (cm)				2.134	0.144
<5	49	21 (42.9%)	28 (57.1%)
≥5	56	32 (57.1%)	24 (42.9%)
Histological type				1.177	0.278
Adenocarcinoma	66	36 (54.5%)	30 (45.5%)
Other	39	17 (43.6%)	22 (56.4%)
T stage				11.675	0.001
1-2	53	18 (34.0%)	35 (66.0%)
3-4	52	35 (67.3%)	17 (32.7%)
N stage				13.414	<0.001
0-1	60	21 (35.0%)	39 (65.0%)
2-3	45	32 (71.1%)	13 (28.9%)

表2 影响胃癌患者预后的危险因素

Tab.2 Risk factors affecting prognosis of patients with gastric cancer

Characteristic	Univariate analysis		Multivariate analysis
Characteristic	Log rank χ²	P	HR	95% CI	P
Gender (male vs female)	1.451	0.228	-	-	-
Age (≥60 years vs <60 years)	1.356	0.244	-	-	-
TSR2 expression (low vs high)	31.840	<0.001	0.418	0.201-0.871	0.020
CEA (≥5μg/L vs <5 μg/L)	18.367	<0.001	2.173	1.126-4.192	0.021
CA19-9 (≥37 kU/L vs <37 kU/L)	25.491	<0.001	3.144	1.559-6.342	0.001
Tumor size (≥5 cm vs <5 cm)	2.163	0.141	-	-	-
Histological type(adenocarcinoma vs other)	0.001	0.982	-	-	-
T stage (T₃-T₄vs T₁-T₂)	21.658	<0.001	1.991	1.034-3.832	0.039
N stage (N₂-N₃vs N₀-N₁)	26.362	<0.001	2.106	1.090-4.066	0.027

图2 胃癌组织中TSR2表达水平对患者术后5年生存率的影响

Fig.2 Influence of TSR2 expression level in gastric cancer tissue on 5-year survival rate of the patients after surgery.

图3 TSR2的KEGG和GO富集分析

Fig.3 KEGG and GO enrichment analysis of TSR2. A: KEGG analysis of TSR2 in gastric cancer. B: GO analysis of TSR2 in gastric cancer.

图4 TSR2对MGC-803细胞增殖能力的影响

Fig.4 Effect of TSR2 overexpression and knockdown on proliferation of MGC-803 cells. A, B: Lentivirus-mediated TSR2 overexpression and knockdown in MGC803 cells. C: TSR2 overexpression inhibits proliferation of gastric cancer cells (n=3). LV: Overexpression; Si: SiRNA. *P<0.05 vs Control.

图5 TSR2对MGC-803细胞迁移和侵袭能力的影响

Fig.5 Effects of TSR2 overexpression and knockdown on migration (A) and invasion (B) of MGC-803 cells detected by Transwell assay (n=3). *P<0.05 vs Control.

图6 TSR2调控MGC-803细胞中的PI3K/AKT信号通路

Fig.6 Western blotting for assessing the effect of TSR2 overexpression and knockdown on expression of p-PI3K and p-AKT in MGC803 cells (n=3). *P<0.05 vs Control.

参考文献 38

1	Mülder DT, Hahn AI, Huang RJ, et al. Prevalence of gastric precursor lesions in countries with differential gastric cancer burden: a systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2024: S1542-S3565(24)00227-1. DOI: 10.1016/j.cgh.2024.02.023
2	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492
3	Digklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives[J]. World J Gastroenterol, 2016, 22(8): 2403-14. DOI: 10.3748/wjg.v22.i8.2403
4	Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer[J]. Lancet, 2020, 396(10251): 635-48. DOI: 10.1016/s0140-6736(20)31288-5
5	朱正纲. 胃癌外科综合治疗的若干进展与展望[J]. 外科理论与实践, 2023, 28(1): 1-6.
6	Song ZY, Wu YY, Yang JB, et al. Progress in the treatment of advanced gastric cancer[J]. Tumour Biol, 2017, 39(7): 101042831771462. DOI: 10.1177/1010428317714626
7	Brisinda G, Chiarello MM, Crocco A, et al. Postoperative mortality and morbidity after D2 lymphadenectomy for gastric cancer: a retrospective cohort study[J]. World J Gastroenterol, 2022, 28(3): 381-98. DOI: 10.3748/wjg.v28.i3.381
8	Feng F, Tian YZ, Xu GH, et al. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer[J]. BMC Cancer, 2017, 17(1): 737. DOI: 10.1186/s12885-017-3738-y
9	de Manzoni G, Yang HK. Gastric cancer surgery[J]. Updat Surg, 2018, 70(2):155. DOI: 10.1007/s13304-018-0551-3
10	贾祺, 咸小红, 李泱润, 等. MAGE-A家族在胃癌中作用的研究进展[J]. 中南大学学报: 医学版, 2023, 48(2): 260-7.
11	Zhao QF, Cao L, Guan LL, et al. Immunotherapy for gastric cancer: dilemmas and prospect[J]. Brief Funct Genomics, 2019, 18(2): 107-12. DOI: 10.1093/bfgp/ely019
12	Zheng CH, Xu YC, Zhao G, et al. Outcomes of laparoscopic total gastrectomy combined with spleen-preserving hilar lymphadenectomy for locally advanced proximal gastric cancer: a nonrandomized clinical trial[J]. JAMA Netw Open, 2021, 4(12): e2139992. DOI: 10.1001/jamanetworkopen.2021.39992
13	Lin XL, Han T, Xia Q, et al. CHPF promotes gastric cancer tumorigenesis through the activation of E2F1[J]. Cell Death Dis, 2021, 12(10): 876. DOI: 10.1038/s41419-021-04148-y
14	Feng YY, Zhao M, Wang LJ, et al. The heterogeneity of signaling pathways and drug responses in intrahepatic cholangiocarcinoma with distinct genetic mutations[J]. Cell Death Dis, 2024, 15(1): 34. DOI: 10.1038/s41419-023-06406-7
15	He HJ, Bing H, Liu GJ. TSR2 Induces laryngeal cancer cell apoptosis through inhibiting NF‑κB signaling pathway[J]. Laryngoscope, 2018, 128(4): E130-4. DOI: 10.1002/lary.27035
16	He HJ, Zhu D, Sun J, et al. The Novel protein TSR2 inhibits the transcriptional activity of nuclear factor‑κB and induces apoptosis[J]. Mol Biol, 2011, 45(3): 451-7. DOI: 10.1134/s0026893311020099
17	Zhao QX, Rangan R, Weng SN, et al. Inhibition of ribosome biogenesis in the epidermis is sufficient to trigger organism-wide growth quiescence independently of nutritional status in C. elegans[J]. PLoS Biol, 2023, 21(8): e3002276. DOI: 10.1371/journal.pbio.3002276
18	Bu DC, Luo HT, Huo PP, et al. KOBAS-i: intelligent prioritization and exploratory visualization of biological functions for gene enrichment analysis[J]. Nucleic Acids Res, 2021, 49(W1): W317-25. DOI: 10.1093/nar/gkab447
19	Sun XZ, Chen PX, Chen X, et al. KIF4A enhanced cell proliferation and migration via Hippo signaling and predicted a poor prognosis in esophageal squamous cell carcinoma[J]. Thorac Cancer, 2021, 12(4): 512-24. DOI: 10.1111/1759-7714.13787
20	Thrift AP, El-Serag HB. Burden of gastric cancer[J]. Clin Gastroenterol Hepatol, 2020, 18(3): 534-42. DOI: 10.1016/j.cgh.2019.07.045
21	Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors[J]. J Surg Oncol, 2013, 107(3): 230-6. DOI: 10.1002/jso.23262
22	Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention[J]. Cancer Epidemiol Biomarkers Prev, 2014, 23(5): 700-13. DOI: 10.1158/1055-9965.epi-13-1057
23	Maddineni G, Xie JJ, Brahmbhatt B, et al. Diet and carcinogenesis of gastric cancer[J]. Curr Opin Gastroenterol, 2022, 38(6): 588-91. DOI: 10.1097/mog.0000000000000875
24	Yusefi AR, Bagheri Lankarani K, Bastani P, et al. Risk factors for gastric cancer: a systematic review[J]. Asian Pac J Cancer Prev, 2018, 19(3): 591-603.
25	Ansari S, Gantuya B, Tuan VP, et al. Diffuse gastric cancer: a summary of analogous contributing factors for its molecular pathogenicity[J]. Int J Mol Sci, 2018, 19(8): 2424. DOI: 10.3390/ijms19082424
26	Guo ZJ, Guo L. Abnormal activation of RFC3, A YAP1/TEAD downstream target, promotes gastric cancer progression[J]. Int J Clin Oncol, 2024, 29(4): 442-55. DOI: 10.1007/s10147-024-02478-3
27	Rong L, Li ZD, Leng X, et al. Salidroside induces apoptosis and protective autophagy in human gastric cancer AGS cells through the PI3K/Akt/mTOR pathway[J]. Biomed Pharmacother, 2020, 122: 109726. DOI: 10.1016/j.biopha.2019.109726
28	Zanotelli MR, Zhang J, Reinhart-King CA. Mechanoresponsive metabolism in cancer cell migration and metastasis[J]. Cell Metab, 2021, 33(7): 1307-21. DOI: 10.1016/j.cmet.2021.04.002
29	Wan GQ, Liu YH, Zhu J, et al. SLFN5 suppresses cancer cell migration and invasion by inhibiting MT1-MMP expression via AKT/GSK-3β/β-catenin pathway[J]. Cell Signal, 2019, 59: 1-12. DOI: 10.1016/j.cellsig.2019.03.004
30	Yang YM, Karbstein K. The chaperone Tsr2 regulates Rps26 release and reincorporation from mature ribosomes to enable a reversible, ribosome-mediated response to stress[J]. Sci Adv, 2022, 8(8): eabl4386. DOI: 10.1126/sciadv.abl4386
31	Yang YM, Jung Y, Abegg D, et al. Chaperone-directed ribosome repair after oxidative damage[J]. Mol Cell, 2023, 83(9): 1527-37, e5. DOI: 10.1016/j.molcel.2023.03.030
32	Fernández-Parejo N, Lorenzo-Martín LF, García-Pedrero JM, et al. VAV2 orchestrates the interplay between regenerative proliferation and ribogenesis in both keratinocytes and oral squamous cell carcinoma[J]. Sci Rep, 2024, 14(1): 4060. DOI: 10.1038/s41598-024-54808-0
33	Zang Y, Ran X, Yuan J, et al. Genomic hallmarks and therapeutic targets of ribosome biogenesis in cancer[J]. Brief Bioinform, 2024, 25(2): bbae023. DOI: 10.1093/bib/bbae023
34	An Y, Xia YC, Wang ZY, et al. Clinical significance of ribosome production factor 2 homolog in hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol, 2024, 48(3): 102289. DOI: 10.1016/j.clinre.2024.102289
35	Miricescu D, Totan A, Stanescu-Spinu II, et al. PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects[J]. Int J Mol Sci, 2020, 22(1): 173. DOI: 10.3390/ijms22010173
36	Sun TS, Bi FF, Liu ZN, et al. TMEM119 facilitates ovarian cancer cell proliferation, invasion, and migration via the PDGFRB/PI3K/AKT signaling pathway[J]. J Transl Med, 2021, 19(1): 111. DOI: 10.1186/s12967-021-02781-x
37	Fresno Vara JA, Casado E, de Castro J, et al. PI3K/Akt signalling pathway and cancer[J]. Cancer Treat Rev, 2004, 30(2): 193-204. DOI: 10.1016/j.ctrv.2003.07.007
38	Maiello D, Varone M, Vicidomini R, et al. Dyskerin downregulation can induce ER stress and promote autophagy via AKT-mTOR signaling deregulation[J]. Biomedicines, 2022, 10(5): 1092. DOI: 10.3390/biomedicines10051092

[1]	王妍, 阮毓卿, 崔璨, 王秀. 交泰丸通过激活PI3K/AKT信号通路改善阿尔茨海默病模型小鼠大脑的葡萄糖代谢[J]. 南方医科大学学报, 2024, 44(5): 894-903.
[2]	王媛媛, 陈腾, 从小凡, 李依然, 陈蕊, 张配, 孙小锦, 赵素容. 扁蒴藤素通过活性氧调控PI3K/AKT通路增强顺铂诱导鼻咽癌细胞凋亡[J]. 南方医科大学学报, 2024, 44(5): 904-912.
[3]	杨晶晶, 殷丽霞, 段婷, 牛民主, 何震东, 陈心蕊, 张小凤, 李静, 耿志军, 左芦根. 胃癌组织中高表达ATP5A1与患者术后的不良预后和肿瘤细胞的糖代谢有关[J]. 南方医科大学学报, 2024, 44(5): 974-980.
[4]	黄秋虎, 周建, 王子珍, 杨堃, 陈政纲. miR-26b-3p 靶向 CREB1 调控神经胶质瘤细胞的增殖、迁移及侵袭[J]. 南方医科大学学报, 2024, 44(3): 578-584.
[5]	梁一豪, 赖颖君, 袁燕文, 袁炜, 张锡波, 张拔山, 卢志锋. 基于GEO数据库筛选胃癌差异表达基因及其功能和通路富集分析[J]. 南方医科大学学报, 2024, 44(3): 605-616.
[6]	朱瑾, 欧阳欣, 刘屿, 钱叶梅, 夏斌, 施延安, 俞力夫. miR-132-3p/CAMTA1对I-125粒子处理的面神经损伤大鼠施万细胞的调控作用[J]. 南方医科大学学报, 2024, 44(3): 571-577.
[7]	沈梦迪, 赵娜, 邓晓晶, 邓敏. COX6B2在胃癌组织中高表达并影响患者的远期预后：基于抑制p53信号调控胃癌细胞的增殖及细胞周期[J]. 南方医科大学学报, 2024, 44(2): 289-297.
[8]	王娟, 杨雯钦, 刘进, 石金凤, 肖萍, 李美香. 脂联素通过上调PPARα/HOXA10通路改善多囊卵巢综合征大鼠的子宫内膜容受性[J]. 南方医科大学学报, 2024, 44(2): 298-307.
[9]	吴广阳, 宋添力, 唐浪, 王一民, 刘绪, 黄胜. 竹节参总皂苷缓解CCl4诱导的大鼠急性肝损伤：基于调控PI3K/Akt/NF-κB信号通路[J]. 南方医科大学学报, 2024, 44(2): 244-251.
[10]	张诺, 张震, 张雨路, 宋雪, 张小凤, 李静, 左芦根, 胡建国. PCID2在胃癌组织中高表达并通过调控细胞周期进程和增殖影响患者预后[J]. 南方医科大学学报, 2024, 44(2): 324-332.
[11]	张文静, 张诺, 杨子, 张小凤, 孙奥飞, 王炼, 宋雪, 耿志军, 李静, 胡建国. BZW1 高表达促进胃癌细胞的侵袭和转移：基于调控Wnt//β-catenin通路和促进上皮间质转化[J]. 南方医科大学学报, 2024, 44(2): 354-362.
[12]	段婷, 张震, 施金冉, 肖林雨, 杨晶晶, 殷丽霞, 张小凤, 耿志军, 陆国玉. CPNE3在胃癌中高表达并与患者的预后不良相关[J]. 南方医科大学学报, 2024, 44(1): 129-137.
[13]	冯雯, 赖跃兴, 王静, 徐萍. 长链非编码RNA ABHD11-AS1促进胃癌细胞糖酵解并加速肿瘤恶性进展[J]. 南方医科大学学报, 2023, 43(9): 1485-1492.
[14]	刘雪柔, 杨玉梅, 蔡慧, 张耀帅, 范方田, 李娴, 李姗姗. 阿美替尼具有较好的抗神经母细胞瘤作用：基于下调MMP2和MMP9的表达[J]. 南方医科大学学报, 2023, 43(9): 1493-1499.
[15]	王炼, 夏勇生, 张震, 刘馨悦, 施金冉, 王月月, 李静, 张小凤, 耿志军, 宋雪, 左芦根. 高表达MRPL13促进胃癌细胞增殖并影响患者预后：基于抑制p53信号[J]. 南方医科大学学报, 2023, 43(9): 1558-1566.